Driving personalized medicine: capturing maximum net present value and optimal return on investment

被引:0
作者
Roth, Mollie
Keeling, Peter
Smart, Dave
机构
关键词
benchmark; companion diagnostic; drivers; financial metrics; model; net present value; NPV; personalized medicine; return on investment; ROI; targeted therapy; DRUG DEVELOPMENT;
D O I
10.2217/PME.09.64
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In order for personalized medicine to meet its potential future promise, a closer focus on the work being carried out today and the foundation it will provide for that future is imperative. While big picture perspectives of this still nascent shift in the drug-development process are important, it is more important that today's work on the first wave of targeted therapies is used to build specific benchmarking and financial models against which further such therapies may be more effectively developed. Today's drug-development teams need a robust tool to identify the exact drivers that will ensure the successful launch and rapid adoption of targeted therapies, and financial metrics to determine the appropriate resource levels to power those drivers. This special report will describe one such benchmarking and financial model that is specifically designed for the personalized medicine field and will explain how the use of this or similar models can help to capture the maximum net present value of targeted therapies and help to realize optimal return on investment.
引用
收藏
页码:103 / 114
页数:12
相关论文
共 17 条
  • [1] [Anonymous], 2007, IMS ADV ONC AN MAT Q
  • [2] Association between short-term effectiveness of statins and long-term adherence to lipid-lowering therapy
    Benner, JS
    Pollack, MF
    Smith, TW
    Bullano, MF
    Willey, VJ
    Williams, SA
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2005, 62 (14) : 1468 - 1475
  • [3] OUTLOOK The microeconomics of personalized medicine: today's challenge and tomorrow's promise
    Davis, Jerel C.
    Furstenthal, Laura
    Desai, Amar A.
    Norris, Troy
    Sutaria, Saumya
    Fleming, Edd
    Ma, Philip
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2009, 8 (04) : 279 - 286
  • [4] NEW DRUG DEVELOPMENT IN THE UNITED-STATES FROM 1963 TO 1992
    DIMASI, JA
    SEIBRING, MA
    LASAGNA, L
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 55 (06) : 609 - 622
  • [5] DUTTON G, MOL DIAGNOSTICS CLIN
  • [6] Payer perspectives on pharmacogenomics testing and drug development
    Epstein, Robert S.
    Frueh, Felix W.
    Geren, Dawn
    Hummer, Doris
    McKibbin, Scott
    O'Connor, Susan
    Randhawa, Gurvaneet
    Zelman, Benjamin
    [J]. PHARMACOGENOMICS, 2009, 10 (01) : 149 - 151
  • [7] Kaitin KI, 2000, DRUG INF J, V34, P673, DOI 10.1177/009286150003400303
  • [8] KECKLY P, 2009, ROI TARGETED THERAPI
  • [9] KEELING P, 2008, PHARM EXECUTIVE OCT
  • [10] Phillips KA, 2008, CURR OPIN MOL THER, V10, P260